Premium
Serum copper level in ovarian carcinoma
Author(s) -
Margalioth Ehud J.,
Udassin Raphael,
Maor Josef,
Schenker Josef G.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850815)56:4<856::aid-cncr2820560425>3.0.co;2-q
Subject(s) - medicine , ovarian carcinoma , chemotherapy , carcinoma , ovary , epithelioma , ovarian cancer , ovarian carcinomas , oncology , pathology , gastroenterology , gynecology , cancer
Serum copper levels (SCL) were determined before any diagnostic procedure was performed or treatment given in 40 women admitted for the investigation of a pelvic mass and, later, in those patients with ovarian carcinoma after chemotherapy and before a second‐look operation was performed. Patients with ovarian carcinoma were found to have significantly higher SCL than patients with benign ovarian lesions. A SCL of 150 μg/dl clearly separated patients with a pelvic mass on the basis of ovarian carcinoma and those with benign noninflammatory pelvic lesions. The same SCL of 150 μg/dl separated patients with ovarian carcinoma that responded to chemotherapy and those with residual disease. It is suggested that SCL be included as a member of the screening panel of biologic tumor markers in general and in ovarian carcinoma in particular.